Kuros Biosciences

Will you be attending this year's Eurospine conference in Vienna, Austria? Visit the Kuros booth #E11 where you can explore the recent Level 1 human clinical data featuring MagnetOsᵀᴹ now published in 𝙎𝙥𝙞𝙣𝙚 and discover our innovative NeedleGripᵀᴹ surface technology. ¹ #Eurospine #MagnetOs #GrowBoneMagnetOs Reference: Stempels, et al. Spine. 2024;49(19):1323-1331.

We are happy to celebrate that last week, Cesar Silva, MD. Senior Director of Clinical Affairs at Kuros Biosciences presented data from the MAXA study recently published in 𝙎𝙥𝙞𝙣𝙚 at the Brazilian Conference of Neurosurgery in Belo Horizonte. The presentation was 𝗮𝘄𝗮𝗿𝗱𝗲𝗱 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗧𝗢𝗣 𝟭𝟬 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀 of innovation and relevance of the conference! We congratulate Cesar and the continued Kuros clinical initiatives that foster bone healing evidence-based decision making. #MagnetOs #BrazilianConferenceofNeurosurgery #KurosBiosciences #Level1Data

Be on the lookout for our upcoming advertisement in the pre-NASS issue of Orthopedics This Week Magazine (OTW)! Our ad highlights a Level 1 investigator-initiated clinical study now published in 𝙎𝙥𝙞𝙣𝙚, where MagnetOsᵀᴹ was used standalone demonstrating a 79% fusion rate compared to 47% for autograft in PLF.¹ As a leader in musculoskeletal biologics, we are proud to support and engage with the vibrant community of orthopedic professionals who are shaping the future of patient care and innovation. A huge thank you to Orthopedics This Week for the opportunity to connect with such a dedicated audience. To learn more about this Level 1 clinical study, click here → https://lnkd.in/eWapu_mt #MagnetOs #KurosBiosciences #Level1Data #OTW #GrowBoneMagnetOs

We’re excited to share that our Scientific Affairs Manager, Luuk van Dijk, PhD, was given the opportunity to present at the 𝟮𝟰𝘁𝗵 𝗦𝘄𝗶𝘀𝘀 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗼𝗳 𝗦𝗽𝗶𝗻𝗮𝗹 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 (𝗦𝗚𝗦) 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 in Basel. Luuk delivered two insightful presentations and was even honored with the "𝗕𝗲𝘀𝘁 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻" 𝗮𝘄𝗮𝗿𝗱! 𝟭. 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Luuk presented a retrospective clinical study on the use of MagnetOsᵀᴹ in interbody spinal fusion in a population with multiple comorbidities, and we’re delighted that his poster won the Best Poster Presentation award. Congratulations, Luuk!   𝟮. 𝗣𝗮𝗽𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Luuk also shared the findings from a prospective, randomized, controlled trial of posterolateral fusion, in which MagnetOs was found to be non-inferior and even indicated superiority to autograft in terms of radiographic fusion rate (79% vs 47% fusion rate).   We extend our sincere thanks to SGS for hosting an engaging event and for supporting the advancement of research in this field. We are looking forward to continued collaboration and progress in pushing the boundaries of innovation! #MagnetOs #SGS #KurosBiosciences #Level1Data

A company dedicated to advancing in the musculoskeletal biologics market! Learn about recent publication of Level 1 human clinical data in the esteemed 𝙎𝙥𝙞𝙣𝙚 journal. Ortho Summit Kuros Biosciences

We're thrilled to announce that Kuros Biosciences will be sponsoring both a faculty dinner and an investor booth at the upcoming 𝗢𝗦𝗘𝗧 𝗦𝘂𝗺𝗺𝗶𝘁 𝗛𝗲𝗮𝗹𝘁𝗵𝗽𝗼𝗶𝗻𝘁 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 event in 𝗟𝗮𝘀 𝗩𝗲𝗴𝗮𝘀, 𝗡𝗩 𝗼𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟯𝘁𝗵. As a company dedicated to advancing in the musculoskeletal biologics market, we're proud to showcase our commitment to data-driven innovation. Our recent publication of Level 1 human clinical data in the esteemed 𝙎𝙥𝙞𝙣𝙚 journal underscores our dedication to rigorous research and cutting-edge technology. We look forward to connecting with industry leaders and visionaries in Las Vegas! #OSETSummit #KurosBiosciences

Great day with Kuros Biosciences 🚀 in London, meeting institutional investors. Many thanks to Chris Fair and Daniel Geiger!

Will you be attending this year's SMISS annual forum in Las Vegas, NV? Visit the 𝗞𝘂𝗿𝗼𝘀 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟭𝟭 where you can explore the recent Level 1 human clinical data featuring MagnetOsᵀᴹ 𝗻𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝙎𝙥𝙞𝙣𝙚 and discover our innovative NeedleGripᵀᴹ surface technology. #SMISS #MagnetOs #Level1Data #KurosBiosciences

Kuros Biosciences is pleased to report financial results for the first half of 2024 which have shown an extraordinary 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗼𝗳 𝟭𝟱𝟵% 𝗶𝗻 𝗱𝗶𝗿𝗲𝗰𝘁 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝘀𝗮𝗹𝗲𝘀 from H1 2023.   Financial highlights also include significant increases in total Kuros medical device segment sales, EBITDA, cash and cash equivalents.   In addition to impressive financial highlights, 𝗞𝘂𝗿𝗼𝘀 𝗵𝗮𝗱 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹, 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗛𝟭 𝟮𝟬𝟮𝟰 including Level 1 human clinical study outcomes published in Spine, new FDA clearances, and the launch of MagnetOs Granules and MagnetOs Putty in New Zealand.   Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “We are pleased to report first half 2024 results that continue to demonstrate our strong execution and commercialization, with direct MagnetOs revenue growth of 159% fueling the MagnetOs EBITDA margin of 27% and total Kuros Group EBITDA margin of 2%, adjusted at 12.5%. Our growing body of clinical evidence, including our recently published MAXA Level 1 clinical study in the peer-reviewed journal Spine, demonstrates how our differentiated technology continues to surpass expectations in providing compared to autograft a superior bone healing solution to surgeons and patients. With additional clearances from the FDA and other regulatory bodies currently applied for, we look forward to driving steady penetration of MagnetOs in the musculoskeletal biologics market.”   To read the full press release, click here → https://lnkd.in/eynjsYTm

OK, 𝙘𝙖𝙧𝙙𝙨 𝙤𝙣 𝙩𝙝𝙚 𝙩𝙖𝙗𝙡𝙚… There’s a lot we could say about the four MagnetOs™ bone grafts now FDA-cleared for interbody procedures. * But sometimes it’s best to just let the surgeon’s hands do the talking. Watch this one-minute POV video of a PLF and TLIF being performed with MagnetOs Flex Matrix → https://lnkd.in/edd-VBBV